Hemophagocytic lymphohistiocytosis in inflammatory bowel disease: a nationwide analysis

Mahmoud, Amir; Abdelhay, Ali; Khamis, Alia; Mostafa, Mariam; Shehadah, Ahmed; Mohamed, Mohamed Salah; Eltaher, Basant; Malik, Talha A.

doi:10.1007/s00277-023-05223-4

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HLH can be triggered by a viral infection, especially CMV and EBV, or malignancy [116]. A recent population study included data from hospitalized patients in a nationwide inpatient sample and confirmed a higher incidence of HLH in IBD patients [119]. The recent systematic reviews by Li et al and Brambilla et al on HLH in IBD patients confirmed that the majority of cases are seen in people receiving therapy including thiopurines [116,118].…”

Section: Thiopurinesmentioning

confidence: 93%

See 1 more Smart Citation

Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review

Massano

Bertin

Zingone

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD) is a group of chronic multifactorial inflammatory disorders including two major entities: Crohn’s disease (CD) and ulcerative colitis (UC). Preliminary evidence suggests that patients with IBD may be at increased risk of developing intestinal and extraintestinal cancers (EICs). Actually, little is known about the association between IBD and EICs, and there is ever-growing concern regarding the safety of immunomodulators and biological therapy, which may represent a risk factor for carcinogenesis. Aims: The aim of this review is to summarize the evidence regarding the association between IBD and EICs, the safety of immunomodulators and biological therapy and the management of immunomodulators and biologic agents in IBD patients with prior or current EICs. Results: IBD patients have a higher risk of developing different forms of extraintestinal solid organ tumors and hematological malignancies. Immunomodulators and biological therapy may increase the risk of developing some types of EICs and may be consciously used in patients with IBD and current or prior history of malignancy. Conclusions: Decisions regarding the use of immunomodulators or biological therapies should be made on an individual basis, considering a multidisciplinary approach involving oncologists.

show abstract

Section: Thiopurinesmentioning

confidence: 93%

“…The latest risk may also be present in primary CMV infection. Secondary hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome known for excessive inflammatory reaction and tissue destruction [119]. HLH can be triggered by a viral infection, especially CMV and EBV, or malignancy [116].…”

Section: Thiopurinesmentioning

confidence: 99%